[The effect of antiplatelet therapy on the course of COVID-19].

Numerous studies demonstrate that a new coronavirus infection is associated with an increased risk of thrombosis, which underlies many of the complications of COVID-19. At the same time, many elderly patients with COVID-19 and with concomitant cordial pathology receive antiplatelet therapy to prevent recurrent ischemic events. The aim of this systematic review was to assess the effect of antiplatelet therapy on the risk of thrombotic complications and disease course in SARS-COV-2 infected patients. We carried out the search of the articles published from 2019 to 2021 with the keywords «antiplatelet therapy» and «COVID-19» in the PubMed database. A total of 209 articles were retrieved out of which 16 which were included in the review. According to majority of retrospective studies (7 out of 10 studies, more than 30.000 patients), antiplatelet therapy is associated with a statistically significant and prominent reduction in overall mortality. Several studies showed that antiplatelet therapy positively influences the risks of severe respiratory disorders, need of invasive lung ventilation and decreases the probability of thrombotic events. However the only prospective randomized placebo-controlled study did not show a benefit of antiplatelet therapy in symptomatic patients with mild stable COPD-19. None of the studies reported a negative effect of antiplatelet therapy on the course of a new coronavirus infection. Therefore, to date there is no conclusive evidence based on prospective randomized trials, of a positive effect of antiplatelet therapy on the course of COVID-19. Further research on this issue using the double-blind method is needed. However, there are no reports of significant adverse effects of antiplatelet agents, who have previously been given antiplatelet therapy for secondary prevention.